Ironwood Pharmaceuticals

Media

Business Woman speaking in an office presentation
looking down at two laptops in use in an office
Media Inquiries

Beth Calitri

Corporate Communications, Media Relations
978.417.2031
[email protected]

Social
Linkedin Twitter

  • Sort by Year

Ironwood Pharmaceuticals Presents Positive Final Data from STARS Nutrition, a Phase II Study of Apraglutide in Short Bowel Syndrome with Intestinal Failure (SBS-IF) and Colon in Continuity (CIC) at United European Gastroenterology Week

Ironwood Pharmaceuticals Presents Positive Final Data from STARS Nutrition, a Phase II Study of Apraglutide in Short Bowel Syndrome with Intestinal Failure (SBS-IF) and Colon in Continuity (CIC) at United European Gastroenterology Week
Ironwood Pharmaceuticals Home
Linkedin Twitter
Ironwood has successfully completed the tender offer of VectivBio, a global clinical-stage biotechnology company
pioneering novel, transformational treatments for severe rare gastrointestinal conditions. For more information, click here